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1. Introduction {#sec001}
===============

*Mycobacterium tuberculosis* is a pathogenic organism which causes Tuberculosis. About a quarter of the global population is affected with this disease \[[@pone.0232482.ref001]\]. Due to emerging drug resistant strains, and reduced effectiveness of treatment due to failure in patient adherence to treatment regime leads to complication and failure of treatment \[[@pone.0232482.ref002]\]. Therefore, there is a need to screen for novel antimycobacterial medicinal plant extracts to employ them as complementary and adjuvant medicine along with the conventional chemotherapy to increase the effectiveness and action of chemotherapeutic drugs. Traditionally, plant extracts and their active components have been used to treat many diseases, and the structures of many phytochemicals have been the starting scaffold for the design of synthetic drugs, including aspirin and taxol \[[@pone.0232482.ref003]\]. Plant extracts possess phenolic compounds and their derivatives play an important role to protect the human body against the damage caused by free radicals \[[@pone.0232482.ref004]\].

Many plant extracts and compounds were tested against mycobacteria and few were reported for their antituberculosis activity. Chloroform extracts of *Pterolobium stellatum* (Forssk), *Persea americana* Mill L and *Otostegia integrifolia* Benth L have shown Minimum Inhibitory Concentration (MIC) values of 0.312, 2.5 and 0.312 mg/mL respectively against *M*. *tuberculosis* strain H37R~V~ \[[@pone.0232482.ref005]\]. Methanolic extract of *Aegle marmelos* L, *Glycyrrhiza glabra* L, *Lawsonia inermis* L, *Piper nigrum* L and *Syzygium aromaticum* L, exhibited antituberculosis activity at a range of 0.8 to 100 μg/mL against *M*. *tuberculosis* strain H37R~V~ \[[@pone.0232482.ref006]\]. While ethyl acetate extract of *Piper longum* L inhibited *M*. *smegmatis* at 32 mg/mL \[[@pone.0232482.ref007]\]. Ethanolic extracts of *Boswellia serrata* Roxb.ex, *Datura stramonium* L and *Lavandula stoechas* L inhibited *M*. *tuberculosis* strain H37R~V~ with a MIC in the range of 125 to 250 μg/mL \[[@pone.0232482.ref008]\]. Phytochemicals namely, Distemonanthoside, 4-Methoxygallic acid, Quercetin and Sitosterol 3-*O*-β-[d]{.smallcaps}-glucopyranoside inhibited *M*. *tuberculosis* strain H37R~V~ with a MIC at a range of 31 to 125 μg/mL \[[@pone.0232482.ref009]\]. Oleanolic acid declined the growth and development of *M*. *tuberculosis* strain H37R~V~ at a MIC of 50--200 μg/mL \[[@pone.0232482.ref010]\].

FtsZ protein is a bacterial tubulin homolog involved in the creation of a Z-ring at the site of cell division. FtsZ is a Guanosine TriPhosphate (GTP) / Guanosine DiPhosphate (GDP) binding protein with the ability of polymerising GTP-into protofilaments. Abnormalities in polymerization / GTPase activity will lead to the inhibition of Z-ring which makes the cell elongated and finally leads to the death of an organism \[[@pone.0232482.ref011]\]. This crucial behavior of protein motivated many researchers around the world to focus and design novel inhibitors targeting it. Berberine, chrysophaentins A-H, Cinnamaldehyde, Curcumin and Viriditoxin are potent inhibitors that are known to target GTPase activity of FtsZ \[[@pone.0232482.ref012]\].

Antimycobacterial activity of HXM extracts of three plants namely *Acacia nilotica*, *Aegle marmelos* and *Glycyrrhiza glabra* were studied. *Acacia nilotica*, L *(A*. *nilotica)* belongs to the family of Fabaceae commonly known as Babul, Karuvelam or Kikar. This plant is distributed in all parts of the world. It is used extensively for the treatment of various types of cancers like bone, mouth and skin by traditional healers in different regions of Chattisgarh (India). In West Africa, the root of *A*.*nilotica* is used to treat tuberculosis, the wood is used to treat smallpox and the leaves are used to treat ulcers \[[@pone.0232482.ref013]\]. *A*. *nilotica* extract is used traditionally to treat respiratory related diseases. It has antituberculosis effects and it could serve as lead for developing new antibiotics \[[@pone.0232482.ref014]\]. Traditionally, the plant roots, leaves, flowers, buds has anticancer, antimicrobial, antioxidant, antimutagenic activity and is used for treating cough, dysentery, leprsosy, opthalmia, small pox, skin ulcers and tuberculosis as well as astringent, antispasmodic and aphrodisiac \[[@pone.0232482.ref015]\] and \[[@pone.0232482.ref016]\].

*Aegle marmelos* L, *(A*.*marmelos)* belongs to the Rutaceae family and is also called as bael tree. It is used in indigenous system of Indian medicine. It is native to India and grows wild in Sub-Himalaya from Jhelum, eastwards towards west Bengal, in central and south India \[[@pone.0232482.ref017]\]. It is known to possess antidiabetic, anticancer, antiinflammatory and antimicrobial activity \[[@pone.0232482.ref018]\]. Fruit of *A*. *marmelos* is also used in the treatment of asthma, dyspepsia, diarrhea, digestive, dysentery, hepatitis, sinusitis, tuberculosis and stomachic \[[@pone.0232482.ref019]\]. Compounds isolated from fruit extract of *A*.*marmelos* like coumarins, marmelosin, marmin, xanthotoxol, kaempferol 3 O-rhamnoside and afzelin have been tested against *Mycobacterium tuberculosis* and *Mycobacterium bovis*. Coumarins and marmelosin have shown antimycobacterium activity against *M*. *tuberculosis* H37Rv with an IC~50~ value of 12.46 μg/mL and 4.31 μg/mL \[[@pone.0232482.ref020]\].

*Glycyrrhiza glabra* L *(G*. *glabra)*, belongs to the family Fabaceae. It is also called as Licorice. Rhizome and root of *G*. *glabra* are used as carminative and expectorant by the Chinese, Egyptian, Greek, Indian and Roman civilizations. It is also called as sweet wood and is native to the certain areas of Asia and Mediterranean. It is an old age plant used in traditional medicine for its ethanopharmacological use to cure simple cough to complex cancer and SARS virus \[[@pone.0232482.ref021]\]. Rhizomes and roots are used orally to treat addison disease, diabetes, lung ailments, kidney stones and tuberculosis. It is also used as mild laxative, contraceptive and to improve sexual function \[[@pone.0232482.ref022]\]. The roots of *G*. *glabra* is used traditionally in India to treat pulmonary related diseases, chest ailments, persistent cough and manage tuberculosis \[[@pone.0232482.ref023]\]. Licorice also shows antiplatelet aggregation effects \[[@pone.0232482.ref024]\] and it has the ability to relieve cough from ancient times \[[@pone.0232482.ref025]\].

D-Pinitol, a phytochemical which is predominantly present in all the three HXM extracts (GCMS & HPLC) is studied in detail here. It has the ability to reduce metastasis of human lung cancer \[[@pone.0232482.ref026]\], it has anti-inflammatory, antihyperlipdemic, cardioprotective and antioxidant activities, \[[@pone.0232482.ref027]\] and \[[@pone.0232482.ref028]\]. It is used for cancers of lung, bladder and breast \[[@pone.0232482.ref029]\] and \[[@pone.0232482.ref030]\]. It is also effective in the inhibition and progression of prostate cancer \[[@pone.0232482.ref031]\] and hypoglycemic levels \[[@pone.0232482.ref032]\].

Initially, antimycobacterial screening of HXM extracts of selected plants were carried out, and the extracts that showed activity were further characterized by Gas Chromatography Mass Spectrophotometer (GCMS) and High Performance Liquid Chromatography (HPLC). The HXM extracts were tested individually as well as in combination with two current antimycobacterial drugs namely INH and RIF by determining the MIC and potential synergy. Time-kill studies were done to determine whether the extracts possess bactericidal or bacteriostatic behaviour. Morphology of cells was measured by the cell elongation study. Antioxidant activity of the plant extracts was also studied. The mechanism of action of these HXM extracts / compound were determined by Live/dead assay. The effect of HXM extracts / compound on *M*. *smegmatis* FtsZ were also investigated by GTPase light scattering and q PCR studies.

2. Materials and methods {#sec002}
========================

2.1. Bacterial strain {#sec003}
---------------------

*Mycobacterium smegmatis* strain (ATCC14468) was procured from the Institute of Microbial Technology, (IMTECH), Chandigarh, India. The bacteria were cultured and maintained at a pH 7, temperature at 37°C in Middlebrook 7H9 medium, supplemented with OADC (Oleic acid/bovine Albumin, Dextrose, Catalase). These chemicals were procured from Sigma (Aldrich, St. Louis, USA). OADC (10%) was prepared separately using, 0.06 mL of oleic acid, 5 g of albumin, 0.85 g of sodium chloride, 2 g of dextrose, 3 mg of catalase and 100 mL of filter sterilized distilled water. The mixture was filter sterilized using 0.44μm membrane. It was added separately to the culture medium at 2% concentration (v/v).

2.2 Plant collection {#sec004}
--------------------

Leaves of *A*. *nilotica* were collected from IIT Madras (South India) Campus. Fruits of *A*. *marmelos* (Bael fruit) were collected from a tree near the campus. No specific permission was required for collection of plant parts from the IIT Madras (South India) authorities as they are very common and abundant species in the region. The roots of *G*. *glabra* were purchased from the Maha Raja Herbals, an ayurvedic shop in Chennai (South India). All the three plant species used in the study are neither endangered nor protected. Collected plant samples were identified as leaves of *A*. *nilotica*, fruits of *A*. *marmelos* and roots of *G*. *glabra* by Dr. K.N.Sunil Kumar, Research Officer, HOD Pharmacognosy, Siddha Central Research Institute, Arumbakkam, Chennai, 600106. The samples were deposited in the Herbarium of Siddha Central Research Institute, Arumbakkam, Chennai, 600106. The voucher specimens of the above samples are A14061903N, A14061901M, G14061902G respectively.

2.3. Herbal preparation {#sec005}
-----------------------

The leaves of *A*. *nilotica* were thoroughly washed, rinsed with distilled water and dried overnight in a hot air oven at 37°C. Unripened pulp of *A*. *marmelos* was well macerated and lyophilized into a fine powder. Roots of *G*. *glabra* were broken into small pieces, washed, rinsed with distilled water and dried overnight in a hot air oven and powdered using a hand blender.

2.4. Extraction procedure {#sec006}
-------------------------

20 g of each of the powdered leaves of *A*. *nilotica*, fruit of *A*. *marmelos* and roots of *G*. *glabra* were weighed separately. Each plant powdered sample was defatted with hexane (300 mL) and the mixtures were kept overnight at room temperature with occasional stirring. The hexane treated residues of the above plant parts were filtered separately to remove the fatty volatile mass and partitioned with methanol (150 mL) overnight. Methanol soluble extracts were filtered out, concentrated using a rotavapor in a preweighed flask. This is named as HXM extract.

2.5. Chemicals {#sec007}
--------------

Chemicals and reagents namely Dimethyl sulfoxide (DMSO), 2,2-diphenyl-1-picrylhydrazyl (DPPH), D-Pinitol, GTP, INH, Isopropyl β-D-1-thiogalactopyranoside (IPTG) and RIF were procured from Sigma (Aldrich, St. Louis, USA).

2.6. Antimycobacterial agents {#sec008}
-----------------------------

Antimycobacterial activity of the HXM extracts were compared with two standard antitubercular drugs namely, INH and RIF. Stock solution of INH (1mg/mL) was prepared with sterile distilled water and RIF (1mg/mL) was prepared with DMSO. 100 μl from the stock concentration was made up to 1mL with the corresponding DMSO/ water. Such that maximum concentration of 100 μg/mL was used for the assay.

2.7. High Performance Liquid Chromatography (HPLC) {#sec009}
--------------------------------------------------

A Phenomenex Rezex R-OA organic acid column (300 × 7.8 mm) fitted on a Shimadzu Prominence HPLC and a RI (refractive index) detector were used for the analysis. Elution was carried out at 50°C using 0.6 mL / min of 5 mM H~2~SO~4~. Internal diameter of the HPLC column is 7.8 mm The Shimadzu LC solution software was used to estimate the peak of plant extracts and D-Pinitol Injection volume of the sample was 20 μl. HPLC was followed according to the method as described \[[@pone.0232482.ref033],[@pone.0232482.ref034]\].

2.8. Preparation of D-Pinitol standard solution {#sec010}
-----------------------------------------------

Standard solution was prepared by dissolving 1mg of D-Pinitol in 1 mL of HPLC grade water and filtering it through 0.45 μm filter paper.

2.9. Gas chromatography and mass spectroscopy (GCMS) {#sec011}
----------------------------------------------------

The phytochemical investigation of HXM extracts were performed on a GC-MS, Clarus 500 Gas Chromatograph Perkin Elmer, USA. Capillary standard non-polar column measured dimension was 30Mts. Temperature of the oven was set to 50°C while injection temperature was maintained at 250 °C and injection volume was 1 μL. Plant extracts were rederivatized using BSTFA (*N*,*O*-Bis(trimethylsilyl)trifluoroacetamide).

2.10. Resazurin assay (REMA) {#sec012}
----------------------------

Resazurin microtitre assay was performed as per the reported protocol \[[@pone.0232482.ref035]--[@pone.0232482.ref037]\]. To prepare the inoculum, two loops of the bacteria were suspended in 15 mL of Middlebrook 7H9 medium in sterile vial and the culture was incubated in orbital shaker at 180 rpm. The cultures were taken for the study once it reached an O.D of 0.6--0.7 (JASCO UV Spectrophotomter, 600 nm). Middlebrook 7H9 broth supplemented with OADC (10%) of 100 μL was added to each flat well bottom of a 96 well microtitre plate. Serial two-fold dilutions of three HXM extracts (dissolved in 5% DMSO), D-Pinitol were performed in Middlebrook 7H9 broth to obtain concentration range of 0.75 mg/mL and 100 mg/mL respectively. Concentration of INH and RIF used is 100 μg/mL serves as positive controls. Culture medium alone and culture medium with *M*. *smegmatis* were the blank and negative control. Controls like DMSO and 5% DMSO were also used for the study. *M*.*smegmatis* suspension (100 μL) containing approximately 1x10^6^ CFU/mL was also added to all the wells containing the samples to yield a final volume of 200 μL/ well. The plate was wrapped using aluminium foil and incubated at 37°C for 48 hours. After incubation, Resazurin dissolved in water (0.2 mg/mL) of 20 μL was added to each well and wrapped again in aluminium foil and incubated for 4--5 hours. The change in color of the solution from blue to pink indicates bacterial growth and blue indicates no growth.

2.11. Combinatorial studies between plant extracts and drugs {#sec013}
------------------------------------------------------------

Checkerboard broth microdilution method was performed to find the effect of combination of drugs and plant extracts / phytochemical. Briefly, drugs (INH / RIF) are serially diluted vertically and different concentration of plant extract has been added horizontally in such a way that each concentration of plant extract has been tested in combination with decreasing concentration of the drugs. Middlebrook 7H9 broth of 100 μL was added into all the wells. Two fold serial dilution of drugs (INH / RIF) has been done vertically and 50 μL aliquots of different concentration of HXM plant extracts / compound were arranged for every conjunction to be tested. 100 μL of *M*.*smegmatis* cultures were added uniformly and incubated for 24 hours at 37°C. After the incubation, Resazurin dye of 20 μL (0.02%) was added to all the wells and plates were further incubated for 5 hours. Lowest concentration of antibiotic and plant extracts in combination showing no color change is considered as measure of inhibition of bacterial growth. Synergistic interactions between plant extracts and drugs were calculated by estimating the FIC index, using the formula, (MIC of antibiotic in combination / MIC of antibiotic alone) + (MIC of plant extract in combination / MIC of plant extract alone) \[[@pone.0232482.ref038]\]. The combination is considered synergistic, additive and antagonist based on the FIC index as \< 0.5, 1 or \> 1.5 respectively.

2.12. Time kill assay {#sec014}
---------------------

Combinations of drugs with extracts were employed equivalent to 1 x MIC. 10 mL of treatment mixtures were arranged and inoculated with 20 μL of 2-day old culture to reach a final Optical Density (O.D) of 0.6 (i.e. 2x10^7^ cells). 50 μL aliquots were withdrawn at 0, 1, 2, 3, 4, 5, 6 and 7 days, diluted serially and corresponding dilution was spread plated on 7H10 agar and incubated at 37°C for 48 hours. Bacterial cell colonies were enumerated by help of magnifying lens, and a kill curve response has been plotted between time and Log~10~ Colony Forming Unit (CFU) to determine the mode of action of the combination \[[@pone.0232482.ref039]\].

2.13. Bacteria live / dead assay {#sec015}
--------------------------------

Live / Dead assay was performed as per manufacturers protocol using Baclight kit method \[[@pone.0232482.ref040]\]. Briefly, the bacterial cultures were grown at 37°C and centrifugation done at 10,000 rpm for 10 minutes at 4°C and the supernatant collected were discarded. Pellets were washed in sterile water. HXM extracts, D-Pinitol, INH / RIF were added at 1 x MIC and this setup was kept at 37°C for 4 hr. After incubation, equal amount of Bac light reagent was added, the vials were covered in aluminum foil and incubated at 37°C for 15 minutes. After this, around 2--5 μL of above samples were mounted on the microslide for viewing the dead and live cells using 40x objective using a Carl-Zeiss Fluorescence Microscope (Axio Imager 2 for Life Science Research, Germany). The kit consists of SYTO9 (green fluorescence dye) is read at 480/500 nm and propidium iodide (red fluorescence dye) is read at 490/635 nm. The former stains the bacteria with both intact as well as damaged membranes, and the latter stains only the cells with damaged membranes.

2.14. Cell elongation studies {#sec016}
-----------------------------

The effect of above plant extracts and D-Pinitol on the increase in the *M*. *smegmatis* cells was determined. Briefly, overnight *M*. *smegmatis* grown culture (0.6--0.8 O.D) were treated separately with plant extracts and D-Pinitol (1 x MIC) and incubated for 4 hours at 37°C. Centrifugation was done for treated samples at 10,000 rpm for 10 minutes at 4°C. Supernatant collected was removed and the pellets were washed in sterile Phosphate buffered saline (PBS). This process is repeated two times. About 0.1--0.2 μL of the washed cell pellets were smeared on a clean microscopy slide. Cell morphology was observed at 40x objective under a Carl-Zeiss Bright Field Microscopy (Axio Imager 2 for Life Science Research, Germany) and the elongated cell length was measured using Image J software.

2.15. Inhibition of GTPase {#sec017}
--------------------------

pSAR1 plasmid harbouring *M*. *tuberculosis* FtsZ gene construct in pET15 vector was a generous gift from Dr.Malini Rajagopalan, University of Texas, USA. Plasmid was expressed in BL21DE3 *E*.*coli* strain exposed to IPTG (1mM) and purified by Ni-NTA column chromatography. Expression and purification of the protein was carried according to method described \[[@pone.0232482.ref041]\] and the purity was checked by SDS-PAGE analysis. Inhibition of GTPase was studied according to the method described \[[@pone.0232482.ref012]\]. Briefly, hydrolysis reaction was carried out using FtsZ (12 μM) and GTP (1 mM) in 50 μL reaction buffer with / without HXM extracts and D- Pinitol at a concentration of 1.5 x MIC. They are incubated for 30 minutes at 37°C. Post 30 minutes 0.5 mM Ethylenediaminetetraacetic acid (EDTA) was added to quench the reactions and aliquots of about 5 μL was drawn and 120 μL of malachite green reagent was added and incubated again for 5 minutes at room temperature. This was followed by the addition of 30 μL of 34% Sodium Citrate. Absorbance was read against 630 nm using Enspire plate reader (Perkin-Elmer LS-55, Sparta, NJ) and the obtained results were compared with the standard graph of GTPase against KH~2~PO~4.~

2.16. FtsZ polymerization assay {#sec018}
-------------------------------

FtsZ polymerization results in the formation of protofilament and monitoring the protofilament with a beam of monochromatic light causes scattering of the rays \[[@pone.0232482.ref042]\]. Right angle (90°) light scattering assay was used to study the ability to disrupt the protofilament formation by the selected plant extracts / D- Pinitol at 1.5 x MIC. This was monitored with JASCO Spectrofluorometer with both excitation and emission set at 400 nm. The reactions were carried out using a polymerization buffer (50 mM MoPs, 100 mM MgCl~2~ & 50 mM KCl). Mtb-FtsZ (12 μM) is first incubated with / without plant extracts and D- Pinitol and monitored for 300 seconds to establish the baseline (zero condition). Then, 50 seconds later 1 mM GTP was quickly added by interrupting the measurement and the scatter intensity is measured continuously for 1000 seconds. For all treatments, the time lag addition of GTP was maintained between 5 and 6 seconds \[[@pone.0232482.ref012],[@pone.0232482.ref043]\].

2.17. FtsZ gene expression study {#sec019}
--------------------------------

To ascertain the effect of the HXM extracts / compound on the gene expression of FtsZ, real time-PCR was done as explained by \[[@pone.0232482.ref044]\] with some variations. The housekeeping gene, 16S rRNA rrsB of *M*. *tuberculosis* was used as reference and using this FtsZ gene fold expression was computed by 2^-(ΔΔCt)^ model \[[@pone.0232482.ref045]\]. *M*. *smegmatis* culture at O.D of 0.1 was treated with HXM extracts / compound at 1.5 x MIC \[[@pone.0232482.ref046]\] for 4 hours \[[@pone.0232482.ref047]\] \[[@pone.0232482.ref048]\] and RNA isolation was done by Trizol Reagent method \[[@pone.0232482.ref049]\]. Isolated messenger Ribonucleic acid (mRNA) was transformed to its corresponding complementary deoxyribonucleic acid (cDNA) using cDNA synthesis kit (Takara Bio Inc) and quantified with qPCR, by employing SYBR green reporter. Molecular Probe to obtain the cycle threshold-C~t~ values of untreated (normal) and treated cells. Primers used in the study of FtsZ gene expression are listed in the [S1](#pone.0232482.s005){ref-type="supplementary-material"}--[S12](#pone.0232482.s016){ref-type="supplementary-material"} Figs and [S1](#pone.0232482.s001){ref-type="supplementary-material"}--[S4](#pone.0232482.s004){ref-type="supplementary-material"} Tables.

2.18. Statistical analysis {#sec020}
--------------------------

All the experiments were conducted in triplicates and values are depicted as Mean ± Standard Deviation. One-way ANOVA has been performed on required cases to verify the statistical significance between the treatments and Brown-Forsythe was performed as a post-hoc test for the experiment.

3. Results and discussion {#sec021}
=========================

Due to the resistance acquired by the various mycobacterial strains to the already existing drugs, development of novel and effective drug inhibiting newer targets has become an urgent need \[[@pone.0232482.ref050]\]. Medicinal plants and their constituents could possibly help in identifying new drugs to overcome the disease.

3.1. Characterisation of plant extracts by GCMS and HPLC {#sec022}
--------------------------------------------------------

The presence of D-Pinitol in the three HXM plant extracts were confirmed by both GCMS and HPLC analysis.

### 3.1.1. Gas Chromatography Mass Spectrometry (GCMS) analysis {#sec023}

The various active compounds as identified by the database with their peak number, concentration (peak area %), and retention time (RT) of all three plant extracts and their biological activities of the phytochemicals identified by GCMS analysis are provided in the [S1](#pone.0232482.s005){ref-type="supplementary-material"}--[S12](#pone.0232482.s016){ref-type="supplementary-material"} Figs and [S1](#pone.0232482.s001){ref-type="supplementary-material"}--[S4](#pone.0232482.s004){ref-type="supplementary-material"} Tables. GCMS of three HXM plant extracts *A*.*nilotica*, *A*.*marmelos* and *G*.*glabra* shows the presence of D-Pinitol at the RT of 5.162, 5.160 and 5.169 respectively ([Table 1](#pone.0232482.t001){ref-type="table"}). Mass fragmentation of *A*.*nilotica* at 5.162 min RT and *G*.*glabra* at 5.169 min RT showed 90% similarity index for D-Pinitol. *A*.*marmelos* at 5.160 min RT showed 92% of similarity index ([S1](#pone.0232482.s005){ref-type="supplementary-material"}--[S12](#pone.0232482.s016){ref-type="supplementary-material"} Figs and [S1](#pone.0232482.s001){ref-type="supplementary-material"}--[S4](#pone.0232482.s004){ref-type="supplementary-material"} Tables).

10.1371/journal.pone.0232482.t001

###### GCMS and HPLC analysis of D-Pinitol with the retention time and percentage area of the HXM plant extracts.

![](pone.0232482.t001){#pone.0232482.t001g}

  S.NO       Name                 Retention time   \% Area
  ---------- -------------------- ---------------- ---------
  **GCMS**                                         
  1          *A*.*nilotica*       5.162            31.83
  2          *A*.*marmelos*       5.160            5.86
  3          *G*.*glabra*         5.169            10.98
  **HPLC**                                         
  4          Standard D-Pinitol   10.198           100.00
  5          *A*.*nilotica*       10.187           45.12
  6          *A*.*marmelos*       10.143           48.33
  7          *G*.*glabra*         10.135           55.02

### 3.1.2 High Performance Liquid Chromatography (HPLC) {#sec024}

The compound D-Pinitol is kept as a standard to internalize the comparison with all the three extracts. Standard D-Pinitol produced the optimized peak at 10.198 retention time. Similarly, extracts of *A*. *nilotica*, *A*. *marmelos* and *G*. *glabra* showed the presence of D-Pinitol at the retention time of 10.187, 10.143 and 10.135 respectively at the 10^th^ minute. They occupied the percentage area as 45.12, 48.33 and 55.02 ([Table 1](#pone.0232482.t001){ref-type="table"}). This observation, clearly indicates the presence of natural compound D-Pinitol in the above three HXM extracts. So, D-Pinitol is considered as a compound of interest and taken for further study.

D-Pinitol commonly called as, 3-O-methyl D-Chiro inositol, is reported to have pharmacological significance, including antidiabetic, antiinflammatory, antioxidant and immunosuppressive potential \[[@pone.0232482.ref051]\]. It is used to treat AIDS, cardiovascular problems, hypertension, rheumatism and certain neurological problems \[[@pone.0232482.ref052]\]. D-Pinitol, a well known antidiabetic agent which acts by reducing the hyperglycemic levels \[[@pone.0232482.ref053]\].

3.2. Antimycobacterial activity of plant extracts {#sec025}
-------------------------------------------------

The antimycobacterial activity of the HXM extracts of *A*. *nilotica*, *A*. *marmelos* and *G*. *glabra* are 1.56 ± 0.03 mg/mL, 1.32 ± 0.02 mg/mL, 1.25 ± 0.03 mg/mL, respectively indicating that hexane methanol wash of the plants enhances the activity. D-Pinitol, a predominant phytochemical found in these plants (based on GCMS and HPLC profile) showed MIC of 0.11 **±** 0.01 μg/mL, while commercial drugs namely INH and RIF had a MIC of 4.0 ± 0.06 μg/mL and 2.0 ± 0.04 μg/mL respectively ([Table 2](#pone.0232482.t002){ref-type="table"}).

10.1371/journal.pone.0232482.t002

###### MIC of HXM plant extracts.

![](pone.0232482.t002){#pone.0232482.t002g}

  Name of the plant / Compound   Common Name                        MIC of HXM plant extracts
  ------------------------------ ---------------------------------- ---------------------------
  *Acacia nilotica*              Babool (Leaves)                    1.56 ± 0.03 mg/mL
  *Aegle marmelos*               Bael/Vilvam (Unriped fruit pulp)   1.32 ± 0.02 mg/mL
  *Glycyrrhiza glabra*           Licorice (Dried Root)              1.25 ± 0.03 mg/mL
  D-Pinitol                      \-                                 0.11 **±** 0.01 μg/mL
  Isoniazid                      4.00 ±0.06 μg/mL                   
  Rifampicin                     2.00 ± 0.04 μg/mL                  

Others have also reported that the activity of different plant extracts depend on the solvent used for extraction. Hexane extract of *A*. *marmelos* fruit inhibited *M*. *tuberculosis* strain H37R~V~ growth at 50 μg/mL while methanol extract inhibited at 100 μg/mL \[[@pone.0232482.ref054]\]. Acetone extract of *G*. *glabra* root inhibited *M*. *tuberculosis* strain H37R~V~ in the range of 0.97--1.95 μg/mL \[[@pone.0232482.ref003]\]. Methanol followed by ethylacetate fraction of pomegranate peel inhibited *M*. *smegmatis* mc^2^155 between 3.35 mg/mL to 0.395 mg/mL \[[@pone.0232482.ref012]\]. Glycyrrhizin, a phytochemical from *G*. *glabra* inhibited *M*. *tuberculosis* strain H37R~V~ at 100 μg/mL \[[@pone.0232482.ref055]\]. The plants in this study seem to exhibit antimycobacterial activity.

3.3. Combinatorial interaction between plant extracts / D-Pinitol and commercial drugs like isoniazid and rifampicin {#sec026}
--------------------------------------------------------------------------------------------------------------------

The extracts of *A*. *nilotica*, *A*. *marmelos*, *G*. *glabra* and D-Pinitol are studied in conjunction with INH and RIF in different proportions to test the effect of combination therapy against *M*. *smegmatis*. The results indicated that, these at sub-minimal inhibitory concentration were able to reduce the MIC of both the drugs. HXM extract of *A*. *nilotica* (1.56 mg/mL) reduced the MIC of INH from 4.00 μg/ mL to 0.01 μg/ mL and MIC of RIF from 2.00 μg/ mL to 0.01 μg/ mL (FIC index = 0.29 and 0.31 respectively). HXM extract of *A*. *marmelos* (1.32 mg/ml) reduced the MIC of INH from 4.00 μg/ mL to 0.05 μg/ mL and that of RIF from 2.00 μg/ mL to 0.01 μg/ mL (FIC index = 0.27 and 0.29 respectively). HXM extract of *G*. *glabra* (1.25 mg/mL) decreased the MIC of INH from 4.00 μg/ mL to 0.02 μg/ mL and that of RIF from 2.00 μg/ mL to 0.01 μg/ mL (FIC index = 0.18 and 0.17 respectively). D-Pinitol (0.11 μg/ mL) reduced the MIC of INH from 4.00 μg/ mL to 0.01 μg/ mL and that of RIF from 2.00 μg/ mL to 0.01 μg/ mL (FIC index = 0.16 and 0.18) respectively. These results indicate that these three HXM plant extracts and D-Pinitol combine in synergistic fashion with these two drugs their by reducing their concentration by (8--10 folds) required to inhibit *M*. *smegmatis*.

Published literature indicated that, MIC of RIF is reduced by 64-fold in combination with the acetone extract of *Cremaspora triflora* Thonn against *M*. *smegmatis* ATCC 1441 \[[@pone.0232482.ref056]\]. MIC of INH is reduced by 8 fold in conjunction with ethyl acetate extract of *Knowltonia vesicatoria* L against *M*. *smegmatis* mc2 155 \[[@pone.0232482.ref057]\]. Plumbagin, from *Plumbago zeylanica* L and Ferelenol from *Ferelenol communis* reduced the MIC of INH by 8 fold against *M*.*tuberculosis* strain H37R~V~ \[[@pone.0232482.ref058]\]. Also, Curcumin and demethoxycurcumin reduced the MIC of INH by 16 fold against *M*. *smegmatis* mc^2^ 155 \[[@pone.0232482.ref059]\]. MIC of RIF reduced from 0.015 to 0.00048 mg/mL when given in combination with antitubercular drug SQ109 against *M*. *tuberculosis* strain H37R~V~ \[[@pone.0232482.ref060]\]. Cumene hydroperoxide reduced the MIC of RIF by 16-fold against *M*. *tuberculosis* strain H37R~V~ \[[@pone.0232482.ref061]\].

Though D-Pinitol has been considered as the lead component to test for activity since being a major fraction in GCMS and HPLC analysis, it can also be noted that in addition to D-Pinitol other phytochemicals present in the HXM extracts may also contribute to the anti- mycobacterial activity which may require separate study. Retention Time (RT) comparison with the standard (D-Pinitol) was the only method used in this study to prove the presence of D-Pinitol in the plant extracts. The results of the combination study shown in the form of isobologram (Figs [1](#pone.0232482.g001){ref-type="fig"} and [2](#pone.0232482.g002){ref-type="fig"}) clearly indicates the potential of the HXM extracts as supplement to the drugs at lower concentration for inhibition of *M*.*smegmatis*.

![Interaction of Isoniazid with HXM extracts of a) *A*. *nilotica*, b) *A*. *marmelos* and c) *G*. *glabra* and d) the phytochemical, D-Pinitol against *M*. *smegmatis*.\
Line indicates additivity. Point below the line indicates synergistic interaction between the two drugs. FIC Index a) 0.29, b) 0.27, c) 0.18, d) 0.16.](pone.0232482.g001){#pone.0232482.g001}

![Interaction of rifampicin with extracts of a) *A*. *nilotica*, b) *A*. *marmelos* and c) *G*. *glabra*, and d) the phytochemical, D-Pinitol against *M*. *smegmatis*.\
Line indicates additivity. Points below the line indicates synergistic interaction between the two. FIC Index a) 0.31, b) 0.29, c) 0.17, d) 0.18.](pone.0232482.g002){#pone.0232482.g002}

3.4. Time--kill studies {#sec027}
-----------------------

Extracts of *A*. *nilotica*, *A*. *marmelos* and *G*. *glabra* and D-Pinitol were employed for time-kill studies individually and in combinations with INH and RIF. The values of CFU at 24^th^ hour were represented in [Table 3](#pone.0232482.t003){ref-type="table"}. *M smegmatis* doubling time is 6--8 hours \[[@pone.0232482.ref062]\]. At 24^th^ hour, drug or extracts are not able to prevent the growth of *M*.*smegmatis*. An average of 3 Log fold decline in the growth rate of *M*. *smegmatis* post 48 hours when compared to the untreated control was observed in all the cases. Also the extracts of these plants in combination with INH and RIF showed an average 2 Log reduction in viable cell count when compared to untreated while other *A*.*nilotica* extract in combination showed an equivalent kill-profile similar to INH and RIF alone. The results are given in [S1](#pone.0232482.s005){ref-type="supplementary-material"}--[S12](#pone.0232482.s016){ref-type="supplementary-material"} Figs and [S1](#pone.0232482.s001){ref-type="supplementary-material"}--[S4](#pone.0232482.s004){ref-type="supplementary-material"} Tables. To confirm whether the growth rate retardation activity is governed by time or due to the presence of active constituents of individual extracts, the activity of D-Pinitol in combination, was also investigated which also showed that in combination with INH ([Fig 3a](#pone.0232482.g003){ref-type="fig"}) and RIF ([Fig 3b](#pone.0232482.g003){ref-type="fig"}) a 2 Log retardation in the growth of viable cell count when compared to control was observed. Literature reports that, dihydrofusarubin and RIF combination showed bacteriostatic activity \[[@pone.0232482.ref063]\]. Ethanolic extract of *Andrographis paniculata* Burm showed bacteriostatic activity against *M*. *tuberculosis* in combination with INH \[[@pone.0232482.ref064]\].

![Time kill curves of a) isoniazid, b) rifampicin in combination with the phytochemical D-Pinitol against *M*. *smegmatis*.](pone.0232482.g003){#pone.0232482.g003}

10.1371/journal.pone.0232482.t003

###### CFU/mL for control and treated samples observed at 24 hrs.

![](pone.0232482.t003){#pone.0232482.t003g}

  Treatment             CFU/mL at 10^−2^ dilution
  --------------------- ---------------------------
  Control               614± 3.35
  INH                   522± 4.87
  RIF                   502± 3.51
  *A*.*nilotica*        456±1.89
  *A*.*nilotica*/ INH   416±2.32
  *A*.*nilotica*/ RIF   401±3.21
  *A*.*marmelos*        445±1.91
  *A*.*marmelos*/ INH   404±1.82
  *A*.*marmelos*/RIF    411±2.67
  *G*.*glabra*          434±3.76
  *G*.*glabra* /INH     391± 4.67
  *G*.*glabra* /RIF     386±4.56
  D-Pinitol             401±1.96
  D-Pinitol/ INH        294±1.75
  D-Pinitol/RIF         302±2.25

Minimum inhibitory concentration (MIC) is defined as the lowest drug concentration that shows 90% growth inhibition of *M*. *smegmatis* \[[@pone.0232482.ref065]\], \[[@pone.0232482.ref066]\]. At 1 x MIC, 10% of the organisms which survive at this specific concentration will acclimatize to this conditions and replicates at further time intervals. Thus, an increase in the CFU of the organism is observed in the graph as a function of time ([Fig 3a and 3b](#pone.0232482.g003){ref-type="fig"}). In our study, combination of the drugs and HXM extracts have much less reduction when compared to the extracts or D-Pinitol alone. This decrease could be due to formation (Millard reaction) of adduct between INH/RIF through the amine group with D-Pinitol (sugar). This Millard reaction between reducing sugars and amines were reported in studies\[[@pone.0232482.ref067]\].

3.5. Live/ Dead assay {#sec028}
---------------------

Membrane damage of *M*. *smegmatis* cell wall after incubating with HXM extracts and D-Pinitol were determined using a Fluorescent Microscope, after staining with STY09 and PI ([Fig 4a--4g](#pone.0232482.g004){ref-type="fig"}). Green indicates live and red indicates dead cells, since PI penetrates the damaged cell wall. Treatment with *A*. *marmelos*, *A*. *nilotica*, *G*. *glabra* and D-Pinitol leads to 43.4%, 55.1%, 49.1% and 50.4% cell wall damage respectively ([Fig 4h](#pone.0232482.g004){ref-type="fig"}). Percentage of cell death on treatment with INH and RIF are 31.7% and 49.3% respectively. The observed cell death in treated bacteria which implies that chosen plant HXM extracts and D-Pinitol has the ability to rupture the cell membrane by releasing intracellular contents and cause death.

![Fluoroscence images of *M*. *smegmatis* cells on treatment with a) control, b) isoniazid, c) rifampicin, d) *A*. *marmelos*, e) *A*. *nilotica*, f) *G*. *glabra* and g) D-Pinitol \[Green indicate viable and Red indicates dead (membrane damaged) cells\] h) % of dead cells on treatment (estimated using Baclight dual staining kit).\
P = \*\*\*\* \<(0.0001) when compared with the control.](pone.0232482.g004){#pone.0232482.g004}

Membrane structural integrity of bacterial cell plays a vital factor for the function of the cell membrane by internally maintaining cellular conditions required for metabolism \[[@pone.0232482.ref068]\]. Numerous studies have reported that, plant phytoconstituents play a role in rupturing cell membrane by affecting its structural integrity. Curcumin I was reported to be active against both Gram positive and negative bacteria, with 100% killing at a dose of 36 μg/mL \[[@pone.0232482.ref069]\]. Present study indicates that the concentration of D-Pinitol at 0.1l μg/mL shows cell membrane damage.

3.6. Cell elongation study {#sec029}
--------------------------

Microscopic images of *M*. *smegmatis* on exposure to the plant extracts, the phytochemical D-Pinitol and drugs are shown in [Fig 5a--5g](#pone.0232482.g005){ref-type="fig"}. The length of *M*. *smegmatis* (3.9 ± 0.5 μm) on treatment with HXM extract of *A*. *nilotica* (8.2 ± 1.0 μm), *A*. *marmelos* (15.7 ± 1.2 μm), *G*. *glabra* (13.5 ± 0.5 μm) and D-Pinitol (12.7 ± 0.1 μm) increased by three to five times. INH and RIF treated *M*. *smegmatis* cells also exhibited elongation (9.7 ± 0.6 μm and 11.5 ± 0.2 μm). Histogram of distribution of cell lengths of the control and treated *M*.*smegmatis* bacteria ([Fig 5h](#pone.0232482.g005){ref-type="fig"}) created using ImageJ clearly shows the result of treatment of different combinations.

![(**a**) Elongation of *M*. *smegmatis* cells on treatment with a) control, b) isoniazid, c) rifampicin, d) *A*. *marmelos*, e) *A*. *nilotica*, f) *G*. *glabra* and g) D-Pinitol, arrow indicates elongated cells. h. (**b**) Represents the histogram of distribution of cell lengths of the control and treated *M*.*smegmatis* bacteria as measured using Image J. Three different fields were observed for each of the microslide and 100 bacterial cells were counted per field.](pone.0232482.g005){#pone.0232482.g005}

Plumbagin and totarol increased the bacteria length by seven and five folds \[[@pone.0232482.ref070]\]. Length of *M*. *smegmatis* bacteria increased to three to four folds on treatment with Esculetin and Scopuletin \[[@pone.0232482.ref012]\]. We also observed similar results with these HXM extracts and D-Pinitol indicating that they probably act by inhibiting the first stage of cell division proteins, namely FtsE, FtsX and FtsZ by inducing cell elongation thereby causing cell death. The elongated cells could not undergo cell division this could be due to the nonfunctional septum formation by their action.

3.7. Effect of plant extracts on *M*. *smegmatis* FtsZ GTPase activity {#sec030}
----------------------------------------------------------------------

Since the plant extracts were shown to interfere with cellular morphology leading to elongated cells. The effect of these plant extracts on cell division were probed. Since FtsZ is the prime protein that acts as a choreographer to organize and assemble other cell division machinery, we probed the effect of HXM extracts of these plants over FtsZ activity.

*A*. *nilotica*, *A*. *marmelos* and *G*. *glabra* inhibited the *M*.*tb* FtsZ GTPase activity with an IC~50~ of 1.399, 1.329 and 1.564 mg/mL respectively ([Fig 6a and 6b](#pone.0232482.g006){ref-type="fig"}). D-Pinitol inhibited GTPase activity with an IC~50~ of 1.524 μg/mL. Berberine, served as a positive control here and it inhibited the activity of GTPase with an IC~50~ of 1.861 μg/mL. Compounds like 7-dimethyl-4- methylcoumarin, daphnetin and esculetin have also been reported to inhibit this activity \[[@pone.0232482.ref012]\]. GTPase activity of FtsZ protein is essential for the creation of Z-ring and abnormalities in this function caused by plant based inhibitors will lead to cell death.

![Effect of a) HXM extracts (mg/mL) and b) D-Pinitol (μM) on *M*. *smegmatis* FtsZ - GTPase polymerisation activity. c) FtsZ polymerisation activity measured using 90^ο^ light scattering assay at 1.5 x MIC with FtsZ at 12 μM. Each point represents the mean of three different replicates, d) RT--PCR Gene expression analysis---fold increase in the expression of FtsZ post treatment at 1.5 x MIC. P = \*\*\*\* \<(0.0001) when compared with the control.](pone.0232482.g006){#pone.0232482.g006}

3.8. Polymerisation of FtsZ {#sec031}
---------------------------

In order to further confirm the effect of extracts on polymerisation of the FtsZ, a light scattering experiment is performed using HXM extracts / D-Pinitol at 1.5 x MIC. All the three plant extracts showed a decrease in the rate of protofilament by 50% after 300 seconds, whereas D-Pinitol showed a stable reduction ([Fig 6c](#pone.0232482.g006){ref-type="fig"}). Many natural compounds from plant extracts such as Cinnamic acid, Curcumin \[[@pone.0232482.ref071]\] and Berberine \[[@pone.0232482.ref072]\] are reported to inhibit the polymerisation activity.

3.9. Studies on gene expression of FtsZ {#sec032}
---------------------------------------

In our studies, it was observed that the bacterial cell membrane damage and cell elongation of the treated *M*.*smegmatis* cells take place after 4 hr. Based on this, the gene expression studies of FtsZ was performed after 4 hr incubation. The concentration of HXM extracts and D-Pinitol increased to 1.5 x MIC to exhibit a fold increase in expression of FtsZ gene. The FtsZ gene expression increased by 2.15, 3.34 and 4.19 fold on treatment with *A*. *nilotica*, *A*. *marmelos* and *G*. *glabr*a when compared to untreated. D-Pinitol treatment increased the FtsZ gene expression by about 2.80 fold ([Fig 6d](#pone.0232482.g006){ref-type="fig"}). This indicates that these HXM extracts / D-Pinitol alters the gene expression of FtsZ considerably in addition to affecting the activity of the FtsZ protein. Many natural phenolic compounds and synthetic derivatives of coumarins are reported for the increased expression of *M*. *tuberculosis* FtsZ \[[@pone.0232482.ref012]\].

4. Conclusions {#sec033}
==============

*M*. *smegmatis*, a non pathogenic bacteria, which is closer to *M*. *tuberculosis* in sequence similarity is used in our study to find the effect of plant extracts against it. The *in vitro* synergistic activity of extracts of *A*. *nilotica*, *A*. *marmelos* and *G*. *glabr*a and the phytochemical D-Pinitol (which is found in all three plants extracts) in combination with two drugs namely INH and RIF were also studied. Plant extracts are known to act on multiple targets while INH is known to inhibit the mycolic acid production, a cell wall component \[[@pone.0232482.ref073]\] and RIF is known to act by inhibiting the bacterial DNA dependent RNA synthesis by inhibiting the RNA \[[@pone.0232482.ref074]\].

HXM extracts and the phytochemical, D-Pinitol produced synergistic effects at different subminimal concentration when combined with the drugs. In time kill analysis, treatment of log-phase *M*. *smegmatis* with 1 x MIC concentration resulted in 2 to 3 Log reduction in viable cells indicating that HXM extracts exhibit bacteriostatic activity. The observed decrease in the activity when HXM plant extracts/ D- Pinitol and drugs are combined together could be due to formation (Millard reaction) of adduct between INH/RIF through the amine group with D-Pinitol (sugar). HXM extracts and D-Pinitol also induce damage to the cell membrane of *M*. *smegmatis* by affecting its structural integrity thereby causing cell death.

D-Pinitol is an interesting biological niche that inhibits *M*. *smegmatis* growth, probably by perturbing the cell division process which resulted in an elongated morphology. This implies that it could be a potential lead as an antimycobacterial agent in drug development. So, for the first time the current study has identified a new phytochemical, which could lead a way towards the development of novel antimycobacterial drug. Also, synergy study has indicated that concentration of commercial drug such as INH and RIF could be reduced considerably by combining them with HXM plant extracts which could lead to reduced toxicity of the former and address the emergence of resistant strains.

The current study indicates that the chosen plant extracts / D-Pinitol can be explored for potential leads in tuberculosis therapy. The study has also identified that they affect the cell division process by inhibiting the GTPase activity of Mycobacterium-FtsZ. These plant extracts also altered the expression of *Mycobacterium-*FtsZ gene. Of course, the pharmacokinetics and pharmcodynamics of these combinations need to be studied in animal models before these could be actually taken up further as adjuvant therapy to potentiate the action of commercial drugs or as complementary and alternative therapy.
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Comments

Minor:

1\. Title is incomplete. Title must include the organism worked upon.

2\. Abstract: Do not include the objective as first line of abstract. It should not start with "To....."

3\. Abbreviate the name of the organism/plant wherever its used for the first time in the text.

4\. Units used in the text are not constant. Some values are represented in mg/ml, ug/ml and some in uM. It is very difficult for the readers to understand and compare.

5\. Line 22: Hexane and not 'hexame'

6\. Line 39: in vitro should be italicized here as well as throughout the text.

7\. Line 59: H37RV is incorrect throughout the text. Correct as H37Rv.

8\. Section 2.1 says 7H9 broth was procured from Sigma and section 2.5 says the same is from BD. Please correct.

9\. Line 269: Correct the gene name as 16S rRNA

10\. Line 269: Write Mycobacterium sp. instead of only genus.

11\. Line 283: 'strain of existing drug' does not make sense

12\. Line 297: Write observation instead of statement

13\. Line 323: Remove the author's name for reference 51. Just use number.

Major:

14\. Section 2.10:

a\) If you added plant extract samples after adding 100ul broth, it will change the volume. How did you keep the volume constant?

b\) Why did you use 1mg/ml INH and RIF and not test other concentrations?

c\) Did you use medium control without DMSO as a control for INH?

d\) All volumes used should be fixed. Do not write about 20ul and so.

15\. Why did you use 1X MIC for time kill assay and 1.5X for gene expression studies. Give reference or explanation for selecting these numbers.

16\. Section 3.2, Line 307: 'hexane wash of plants enhances the activity'..did you study unwashed extracts to compare.

17\. Section 3.3: Paragraph 1 results can be represented as a small table for an easy comparison.

18\. Conclusion: Include references for mode of action of INH and RIF (line 442-444).

Reviewer \#3: The phytochemistry that was done to determine the presence and quantity of pinitol is not clear. The paper is lacking any statistical analysis, although this is mentioned in the M&M section.

Please find further comments in the attached PDF.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Dr. Radha Gopalaswamy

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: PONE-D-19-29098_reviewer_1.pdf

###### 

Click here for additional data file.
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Author response to Decision Letter 0

10 Jan 2020

Reviewer \#1: Manuscript Number: PONE-D-19-29098

1, Manuscript Title: Antitubercular activity of plant extracts and their action on cell division protein (FtsZ).The article titled "Antitubercular activity of plant extracts and their action on cell division protein (FtsZ)" talks about possible synergistic effects of plant extracts with anti-mycobacterial drugs which is tested using fast grower M. smegmatis.

The title is quite misleading to any reader with the use of word "anti-tubercular activity". It is preferred to avoid using the term "anti-tubercular activity" in the title.

Response: We have changed the title to" Inhibitory activity of traditional plants against Mycobacterium smegmatis and their action on Filamenting temperature sensitive mutant Z (FtsZ) - a cell division protein".

2, In line 192, under REMA assay under materials and methods section, RIF and INH is used at 1 mg/ml. This contradicts with several earlier reports for MIC values of Rifampicin and isoniazid which are different as estimated visually or by alamar blue or resazurin assay.

Response: The stock of RIF and INH is 1mg/mL in DMSO/ water, from which further 10X dilution was made to avoid DMSO effect. 100 µl from the stock concentration was made up to 1mL with the corresponding DMSO/ water. Such that maximum concentration of 100 µg/mL was used for the assay. We have corrected the above statement under material sections

3, Line 193 under same assay says "The plate was wrapped using aluminium foil and incubated overnight at 37°C for 48 hour". Kindly clarify if left overnight or for 48 hours. This could be useful to anyone who wants to repeat the assay. Besides, drug treatment for MIC determination would be done more than 24 hours for M. smegmatis.

Response: It should be written as, the plate was wrapped using aluminium foil and incubated at 37 °C for 48 hour. The term overnight was wrongly placed. We have corrected the above statement under material sections.

4, Line 195-196 under same assay says "The change in colour of the solution from blue to pink indicates inhibition while no change indicates the growth of bacteria". Actually, the resazurin colour change to pink indicates growth and the statement gives the impression the author(s) is unfamiliar with the protocol.

Response: It should be written as the change in color from blue to pink indicates the growth of bacteria and no change indicates inhibition. The above changes were also made in the text file.

5, In line 205, authors refer to synergy drug testing for 24 hours at 37'C and report differential FIC index. However, in Fig 3 detailing time kill analysis we see no difference in CFU as indicated in the graph. What could be the possible explanation for this.

Response: In antibacterial study, the MIC was observed post 48 hr. hence there was no significant difference in Time kill at the first 24 hr, however the killing effect (Fig 3) can be seen after 48 hr.

6, In line 214, time kill assay was performed at 1x MIC of the drug. However, routinely synergistic drug effects would be tested at sub MIC levels.

Response: Yes, it should be tested under sub MIC levels. But, in synergistic studies, plant extracts acted in subminimal concentration along with the combination of INH/ RIF by reducing the MIC of first line drugs from 4.00 to 0.01 μg/ mL for INH and 2.00 to 0.01 μg/ m for RIF. So,synergy study was performed at lower concentration.

7, In line 271, to study FtsZ gene expression, plant extracts and drugs have been tested at 1.5 x MIC. Is there any reason to use such higher value? Clarity on this will help understand why it was used.

Response: The compounds showed antimycobacterial activity against M.smegmatis at 1x MIC at 48 hr incubation, but in the case of gene expression studies which is done in 4 hr, the effect of 1x MIC may not show significant difference. Hence in order to mitigate the shorter experiment time, we considered a step higher concentration of 1.5x MIC.

8, In line 282, the authors have written that "There has been no new anti tuberculosis drug introduced in the past 30 years". Please remove this statement. The authors could have been more careful while writing this.

Response: We removed the statement. Thank you for sharing the information on drugs.

9, In line 324, the authors claim that "The results indicated that, these at sub-minimal inhibitory concentration were able to reduce the MIC of both the drugs". However, the concentration of the HXM extracts used here are given as the same the MIC values given in supplementary table S4. The statement needs clarification.

Response: In the study, it is observed that combination of the plant extract with current drugs (RIF/INH) were able to reduce the drug dosages required. Rifampicin and Isoniazid alone exhibited MIC at 2.0 µg/mL and 4.0 µg/mL , whereas in combination with the reported plant extracts they exhibited anti-tubercular activity at 0.01 µg/mL and 0.02 µg/mL. Thus we say that these plant extracts were able to synergize with RIF & INH to exhibit activity at their sub-minimal concentration.

10, In lines 363-365, the authors claim 2-log growth retardation when D-Pinitol was used in combination with Rifampicin or Isoniazid. However, in figure 3, D-pinitol by itself shows better/similar retardation independent of anti-TB drugs. What is the possible explanation of this ??

Response: At a concentration of 0.11 µg/mL D- Pinitol showed better MIC activity, whereas first line drug such as Rifampicin, Isoniazid showed MIC of 2.00 and 4.00 µg/ml. This may be the possible reason for D - Pinitol to show its enhanced activity against Mycobacterium smegmatis.

Reviewer \#2: The manuscript is not written in good English. There are many grammatical, topological and convention related errors some of which are mentioned below.

Comments

Minor:

1\. Title is incomplete. Title must include the organism worked upon.

Response: We have changed the title to " Inhibitory activity of traditional plants against Mycobacterium smegmatis and their action on Filamenting temperature sensitive mutant Z (FtsZ) - a cell division protein".

2\. Abstract: Do not include the objective as first line of abstract. It should not start with "To....."

Response: Changes were made in the text

3\. Abbreviate the name of the organism/plant wherever its used for the first time in the text.

Response: Changes were made in the text

4\. Units used in the text are not constant. Some values are represented in mg/ml, ug/ml and some in uM. It is very difficult for the readers to understand and compare.

Response: Values are converted to mg/mL, ug/mL throughout the manuscript

5\. Line 22: Hexane and not 'hexame'

Response: Change was made in the text

6\. Line 39: in vitro should be italicized here as well as throughout the text.

Response: In vitro has changed to In vitro

7\. Line 59: H37RV is incorrect throughout the text. Correct as H37Rv.

Response: H37RV is corrected as H37Rv throughout the document.

8\. Section 2.1 says 7H9 broth was procured from Sigma and section 2.5 says the same is from BD. Please correct.

Response: 7H9 broth was procured from Sigma and was changed in the text file.

9\. Line 269: Correct the gene name as 16S rRNA

Response: The gene name is corrected as 16S rRNA

10\. Line 269: Write Mycobacterium sp. instead of only genus.

Response: M.tuberculosis genus is added

11\. Line 283: 'strain of existing drug' does not make sense

Response: The sentence were corrected.

12\. Line 297: Write observation instead of statement

Response: Change was made in the statement.

13\. Line 323: Remove the author's name for reference 51. Just use number.

Response: We have removed author name.

Major:

14\. Section 2.10:

a\) If you added plant extract samples after adding 100ul broth, it will change the volume. How did you keep the volume constant?

Response: Microplate serial broth-dilution technique was used according to the below reference. Briefly twice the required maximum concentration of the plant extract is added initially, then it is further serially diluted with broth to reach a minimum concentration. To this 100ul of 0.1 O.D culture was added. Thus the volume is kept constant

b\) Why did you use 1mg/ml INH and RIF and not test other concentrations?

Response: The stock of RIF and INH is 1mg/mL of DMSO, from which further 10X dilution was made to avoid DMSO effect .100 µl from the stock concentration was made up to 1mL with the corresponding DMSO/ water. Such that maximum Concentration of 100 µg/mL was used for the assay which is further serially diluted to obtain the minimum concentration that shows inhibition of growth. We have corrected the above statement under material sections.

c\) Did you use medium control without DMSO as a control for INH?

Response: Yes, appropriate controls were followed. Only broth as medium control and DMSO also a control

d\) All volumes used should be fixed. Do not write about 20ul and so.

Response: We corrected the statement

e). Why did you use 1X MIC for time kill assay and 1.5X for gene expression studies. Give reference or explanation for selecting these numbers.

Response:

• 1x MIC was used for time kill based on the synergy studies.

Explanation: In time-kill the concentrations of plant extracts were used at 1x MIC whereas the concentration of drugs (RIF & INH) was used at sub-minimal inhibitory concentration which was found to be effective in synergy. So, subminimal concentration was used.

• In gene expression studies a higher fold concentrations were employed, since gene expression studies are generally done in lesser time span. Thus 1.5x MIC was considered.

f). Section 3.2, Line 307: 'hexane wash of plants enhances the activity'..did you study unwashed extracts to compare.

Response: It should be written as Hexane methanol wash to enhance the activity. We didn't study the unwashed extracts to compare the efficiency. We corrected the statement in the text file

g). Section 3.3: Paragraph 1 results can be represented as a small table for an easy comparison.

Response: Table is included as a separate file.

i). Conclusion: Include references for mode of action of INH and RIF (line 442-444).

Response: References were included for INH and RIF action.

Reviewer \#3:

1, The phytochemistry that was done to determine the presence and quantity of pinitol is not clear.

Response: We have done both GCMS and HPLC for all the three HXM extracts. From HPLC, results of standard D- Pinitol with a retention time at 10.198 min which matches exactly with the retention value of three plants namely A.nilotica, A.marmelos and G.glabra at 10.187, 10.143 and 10.135 respectively confirming the presence of D-Pinitol. Moreover, mass fragmentation was done for major peak of A.nilotica at 5.162 min retension time and G.glabra at 5.169 min retension time which showed 90% similarity index for D- Pinitol. A.marmelos at 5.160 min retension time showed 92% of similarity index . This major peak of all the three HXM extracts matches with the derivatives of D- Pinitol, pentakis(trimethylsilyl) ether of about 90 %. MS fragmentation reports were also attached in the supplementary file.

The paper is lacking any statistical analysis, although this is mentioned in the M&M section.

Response: We included statistical analysis in the data including p value in all the figures as well as one way Anova.

Response for Line 147: Yes, we dried the plant samples in an oven overnight at room temperature (37οC). A oven with a fan is used, which blew air through the trays.

Response for Line 148: Fruit pulp was macerated by using mortar and pestle without using any solvents.

Response for Line 166: Stock solution was prepared 1mg/mL

Response for line 175: The concentration of D- Pinitol to run HPLC is 1mg/mL.

In the whole text, values were converted in to mg and µg/mL.

Response for line 183: Protocol has been changed

Response for line 190: our plant extracts were dissolved at 100mg/mL of 5 % DMSO. We didn't observe any microprecipitation because the extract dissolved completely.

Response for line 191:

The mycobacterium strain was grown in 7H9 medium to an OD of 0.6 and then diluted to attain a cell concentration of 1x106 CFU/ml and added to each well.

Response for line 197: Change has been made

Response for line 224: Centrifugation done at 10,000 rpm which corresponds to 11200g

Response for line 249: Magnification was done at 40X

Response for line 260: HXM extract/ D- Pinitol conc is 1.5 x MIC

Response for line 262: Malachite green was added as a color reagent

Response for line 288: Fragmentation patterns with their similarity index were attached in supplementary file.

Response for line 294-296:. Mass spectra data is attached in supplementary file to confirm the presence of D-Pinitol with a similarity index of 90 % in all the three HXM extracts.

Response for line 307: It should be written as hexane methanol wash of the plants enhances the activity. (Changes were made in the text).

Response for line 310: Values are converted to mg and µg/mL.

Response for line 312: Statement should be written as hexane methanol wash of the plant enhances its activity. However, the cited reference states the increase in the activity of hexane extract of A.marmelos this is may be due to variation of plant sources, method of preparation of extracts, preparation of media and growth condition of organism. Cited paper used M.tuberculois for their experiment. All these factors may influence the MIC values of the extracts.

Response for line 317: The reported value is not inhibition, so we deleted the statement in our text.

Response for line 318: We modified the text.

Reviewer 3 : if D -- Pinitol is the major constituent in all the 3 plant extracts and show an low /miC of 0.58um(lower than positive control). surely, the extracts will show much better activity.

Response for line 346: Yes, we agree with your statement. During combinatorial studies, plant extracts at subminimal concentration i.e., below their MIC values were able to reduce the amount of INH and RIF to 0.01µg/ml to achieve good activity.

Reviewer 3 : This is low activity (A. nilotica, A. marmelos and G. glabra inhibited the M.tb FtsZ GTPase activity with an 415 IC50 of 22.50 ± 1.25, 23.45 ± 1.12 and 37.9 ± 1.19 mg/ml respectively). For a plant extract to be activity it should fall within ug/ml conc range especially for enzymatic assays and kinetics.

Response for line 415 : It should be written as IC50 of 1.399, 1.329, 1.564 mg/mL. All biological activity in this paper was performed in mg level and the concentration level used for this experiment is 0.5 to 2.5mg/mL. So it is expected to fall within mg/mL. Since, D- Pinitol is a phytochemical it expressed GTPase activity in µg/mL. Our study is aimed to design a novel plant inhibitor that reduces the mycobacterial resistance to the other first line drugs.

Reviewer 3 : if the treatment is done at 1.5 times the MIC is expected to see a reduction. An effect should rather be observed at ½, ¼ or 1/8 MIC.

Response : In gene expression studies a higher fold concentrations were employed, since gene expression studies are generally done in lesser time span (4 hr). Thus 1.5x MIC was considered for this study. Whereas MIC studies were performed after 48 hrs of incubation.

Figure 3 : Standard deviations were included.

Figure 4 : Stastical values were added

Figure 5: Stastical values were added and length is changed to µm.

Figure 6: IC 50 values were not calculated for light scattering assay.
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Dear Dr Ravindran,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: The authors need to carefully revise the manuscript for language, grammar and syntax errors.  Also, the response to reviewers\' comments should be included in the manuscript.  Some of the limitations pointed out in the first round of review should be explicitly mentioned in the discussion section. (for example, reviewer\#3 mentioned that the activity was weak since it is in the range of mg/ml rather than ng/ml.)

==============================

We would appreciate receiving your revised manuscript by Mar 13 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Although the manuscript titled "Inhibitory activity of traditional plants against Mycobacterium smegmatis and their action on Filamenting temperature sensitive mutant Z (FtsZ) - a cell division protein" is interesting it is not acceptable for publication in the present version because unless the following concerns are addressed.

Major concerns -

1\. Section 3.3 and 3.4 - The combinatorial effect is performed at 24-hour timepoint in the present study using resazurin assay. But in time kill studies with usage of 1x MIC of drugs/extracts, no difference is seen between the tested samples at 24 hours. No representative figures given for the data of HXM extracts in time kill studies though log differences are mentioned in the text in results section. Also, combination of the drugs and extracts have much less reduction when compared to the extracts or pinitol alone. What is the possible explanation?

2\. In the cell elongation studies (section 3.6), the cell length cannot be given as a mean. It would be preferable to count atleast 100 cells and give a graph of different cell lengths as percentage. 2- 3 um, 4-5 um, so on. That would be a better representative of the study of what percentage is increase in cell length rather than a single value.

3\. In the section 3.7, IC50 value is calculated from linear points and graph for standard compounds looks neither linear or as a dose response. Why were the concentrations chosen as given in the text? They are neither log scale increase nor times MIC. What is the possible reason the authors chose to test them? Is curve fitting done for statistical analysis?

4\. The reason for performing gene expression studies at 1.5X MIC is not scientific. If the authors felt 4 hours is too early then the studies should have been done proper titration of time and x MIC. Otherwise there should be a valid reason authors felt that using 1.5x MIC at 4-hour time point is acceptable. A single point data with no scientific explanation to substantiate the same is not convincing.

Reviewer \#2: The manuscript still has many grammatical and topological errors. Authors should pay attention to sentence formation as well. I strongly recommend that the authors get the manuscript reviewed by an expert before resubmission.

Comments:

Isoniazid and Rifampicin can be abbreviated as INH and RIF respectively throughout the text.

Line 30: Correct as 'Time kill kinetic studies indicate..'

Line 31: 'reduction' would be better than 'retardation'

Line 41: 'in-vitro' is incorrect. Write 'in vitro'.

Line 41: inhibition of FtsZ\...

Line 134-135: Represent in units and not in weight or volume. Also, mention the method of sterlization for OADC.

Line 139-141: Authors probably want to say that 'they' did not need any specific permission for collection. It can be written as 'No specific permission was required for collection of plant parts\....'

Line 143: word 'species' is repeated, please remove from the end.

Line 151: Were the dried leaves powdered or crushed? Pls mention in the text.

Line 155, 195, 212, 216: Do not write 'about' for fixed volumes.

Line 157: How is the mixture undisturbed if it was stirred? Where was it incubated overnight and at what temperature? Pls correct. Write the temperature used for following steps as well.

Line 162: Already mentioned in section 1.

Line 177: Correct as 'elution was carried out at ....'

Line 182: Correct the sentence.

Line 193: Write 'incubated' instead of 'kept'.

Line 195: Mention whether 96 well plates used were U-bottom.

line 197: Mention the range of tested concentrations of 3 plant extracts.

Line 203: 48 hours..

Line 204: 'resazurin dissolved in water'

Line 204: 'after this incubation' is repeated in the same sentence

Line 215: Mention which cultures..

Line 217: Correct as 'plates were further incubated'.

Section 2.10 says that the MIC plates were incubated for 48 hrs while in section 2.11 incubation time is mentioned as 24 hrs. Why is it different for section 2.11? Pls explain.

Line 228: Correct as 'withdrawn at 0, 1, 2, 3, 4, 5, 6 and 7 days, diluted serially and\...'

Line 229: Mention time of incubation for the plates.

Line 235: Have you used 'they' for 'pellet'. Pls correct.

Line 343: The concentrations of plant extracts used are exact MICs. How are these sub-minimal?

Line 375-381: Where are these results shown in the manuscript? These should be represented as a graph and figure number should be mentioned here.

Line 401: Pls explain this estimation.

Line 419: Remove 'an'.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Radha Gopalaswamy

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

13 Feb 2020

Response to the comments

Reviewer \#1: Although the manuscript titled "Inhibitory activity of traditional plants against Mycobacterium smegmatis and their action on Filamenting temperature sensitive mutant Z (FtsZ) - a cell division protein" is interesting it is not acceptable for publication in the present version because unless the following concerns are addressed.

Major concerns --

1\. Section 3.3 and 3.4 --

Comments : The combinatorial effect is performed at 24-hour time point in the present study using resazurin assay. But in time kill studies with usage of 1x MIC of drugs/extracts, no difference is seen between the tested samples at 24 hours.

Response: The values of CFU at 24th hour are represented in the table 1. CFU values for combination therapy is lesser than the individual drug/ plant extract. The drugs INH and RIF are bactericidal in nature ( Ref 1). Mycobacterium smegmatis doubling time is 6-8 hours (Ref 2). So beyond 24 hours, drug or extract are not able to prevent the growth of M.smegmatis. It is difficult to differentiate the effect of various treatments after 24 hours in the time kill.

Table 1

Treatment CFU - 24th hr

Control 614± 3.35

INH 522± 4.87

RIF 502± 3.51

A.nilotica 456±1.89

A.nilotica/INH 416±2.32

A.nilotica/RIF 401±3.21

A.marmelos 445±1.91

A.marmelos/INH 404±1.82

A.marmelos/RIF 411±2.67

G.glabra 434±3.76

G.glabra /INH 391± 4.67

G.glabra /RIF 386±4.56

D-Pinitol 401±1.96

D-Pinitol/ INH 294±1.75

D-Pinitol/RIF 302±2.25

Comments: No representative figures given for the data of HXM extracts in time kill studies though log differences are mentioned in the text in results section.

Response: Representative figures are given in the supplementary data.

Comments: Combination of the drugs and extracts have much less reduction when compared to the extracts or pinitol alone. What is the possible explanation?

Response:

� Isoniazid and Rifampicin are bactericidal in nature (Ref 1) whereas D-Pinitol and the plant extracts are found to be bacteriostatic. Hence in combination, i.e. plant extract or D- Pinitol in higher concentration and drugs in less concentration might alter the effect. This, variation could be observed significantly after 4 days in the time- kill graphs.

� The above same effect was observed for D- Pinitol/ Pencillin combination against MRSA. In which they observed, D- Pinitol in combination with Pencillin, showed less activity when compared with D- Pinitol at 1X MIC (Ref 3).

� The observed decrease in the activity when HXM plant extracts/ D- Pinitol and drugs are combined together could be due to formation (Mailliard reaction) of adduct between INH/RIF through the amine group with D-Pinitol (sugar). This Mailliard reaction between reducing sugars and amines were reported in studies (Ref 4).

� Similar activity observed in plant extracts also. Whereas when D-Pinitol used alone it showed more activity than in combination with other extracts.

� However decrease in potency of antibiotics was observed, particularly when combined with A.nilotica/ INH, A.marmelos/ INH and A.marmelos/ RIF. It was particularly apparent for G.glabra, which was able to inhibit the growth of M.smegmatis, but enhanced its activity when combined with anti-tuberculosis drugs. (INH/RIF) (Supplementary Fig 11&12S).

2\. In the cell elongation studies (section 3.6), It would be preferable to count atleast 100 cells and give a graph of different cell lengths as percentage. 2- 3 um, 4-5 um, so on. That would be a better representative of the study of what percentage is increase in cell length rather than a single value.

Response: Graph with percentage of cells with different length is provided in Figure 5h.

3\. In the section 3.7, IC50 value is calculated from linear points and graph for standard compounds looks neither linear or as a dose response. Why were the concentrations chosen as given in the text? They are neither log scale increase nor times MIC. What is the possible reason the authors chose to test them? Is curve fitting done for statistical analysis?

Response: Yes, The Curve fitting is done and it is represented in Figure 6 a, b. It is done using Graph pad prism. Non linear regression (four parameter model) was performed to obtain the IC50 of the respective treatments.

4\. The reason for performing gene expression studies at 1.5X MIC is not scientific. If the authors felt 4 hours is too early then the studies should have been done proper titration of time and x MIC. Otherwise there should be a valid reason authors felt that using 1.5x MIC at 4-hour time point is acceptable. A single point data with no scientific explanation to substantiate the same is not convincing.

Response: The effect of cell elongation was observed at 4 hr. Hence, we performed the expression studies also at 4 hr. There are studies in which gene expression is performed in response to 90 min, 3 hr and 5 hr exposure also. For eg: Gene expression is done for M.tuberculosis after 3 hr of exposure (Ref 6)

References:

1\. Bacteriostatic and Bactericidal Activity of Antituberculosis Drugs Against Mycobacterium Tuberculosis, Mycobacterium avium-Mycobacterium Intracellulare Complex and Mycobacterium Kansasii in Different Growth Phases, , S Yamori 1, S Ichiyama, K Shimokata, M Tsukamura, Microbiol Immunol, 36 (4), 361-8, 1992.

2\. Adaptation of Mycobacterium smegmatis to Stationary Phase, MARJAN J. SMEULDERS, JACQUIE KEER, RICHARD A. SPEIGHT,† AND HUW D. WILLIAMS, JOURNAL OF BACTERIOLOGY, p. 270--283 Vol(181): 1, 1999.

3\. Synergistic effect of (+)-pinitol from Saraca asoca with β-lactam antibiotics and studies on the in silico possible mechanism, Furkan Ahmad, and Laxminarain Misra, Journal of Asian Natural Products Research 18(2):1-12(2015).

4\. Maillard Reactions in Pharmaceutical Formulations and Human Health, . Int J Pharm Compd, David W Newton, ,,15 (1), 32-40, 2011

5\. Differential Gene Expression in Auristatin PHE-Treated Cryptococcus neoformans Tanja Woyke, Michael E. Berens, Dominique B. Hoelzinger, George R. Pettit, Günther Winkelmann, Robin K. Pettit, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, , p. 561 567(2004) (Gene expression done at 1.5 x MIC in response to 90 min).

6\. Thiol reductive stress induces cellulose-anchored biofilm formation in Mycobacterium tuberculosis,Abhishek Trivedi, Parminder Singh Mavi, Deepak Bhatt & Ashwani Kumar , Nature Communications vol 7: 11392, (2016) .(Gene expression done in response to 3 hr)

Reviewer \#2: The manuscript still has many grammatical and topological errors. Authors should pay attention to sentence formation as well. I strongly recommend that the authors get the manuscript reviewed by an expert before resubmission.

Comments:

Isoniazid and Rifampicin can be abbreviated as INH and RIF respectively throughout the text.

Response: Isoniazid and Rifampicin is abbreviated as INH and RIF throughout the text.

Line 30: Correct as 'Time kill kinetic studies indicate..'

Response: Corrected as Indicated.

Line 31: 'reduction' would be better than 'retardation'

Response: Replaced the word.

Line 41: 'in-vitro' is incorrect. Write 'in vitro'.

Response: Corrected as in vitro

Line 41: inhibition of FtsZ\...

Response: inhibition of FtsZ is added

Line 134-135: Represent in units and not in weight or volume. Also, mention the method of sterlization for OADC.

Response: The mixture was filter sterilized using 0.44µm membrane. It was added separately to the culture medium at 2% concentration (v/v).

Line 139-141: Authors probably want to say that 'they' did not need any specific permission for collection. It can be written as 'No specific permission was required for collection of plant parts\....'

Response: Sentences were corrected

Line 143: word 'species' is repeated, please remove from the end.

Response: the word species is removed.

Line 151: Were the dried leaves powdered or crushed? Pls mention in the text.

Response: It is mentioned as fine powder.

Line 155, 195, 212, 216: Do not write 'about' for fixed volumes.

Response: About is removed

Line 157: How is the mixture undisturbed if it was stirred? Where was it incubated overnight and at what temperature? Pls correct. Write the temperature used for following steps as well.

Response: Sentences were corrected.

Line 162: Already mentioned in section 1.

Response: Line was removed

Line 177: Correct as 'elution was carried out at ....'

Response: Sentence has been corrected

Line 182: Correct the sentence.

Response: Sentence has been corrected.

Line 193: Write 'incubated' instead of 'kept'.

Response: Replaced the word

Line 195: Mention whether 96 well plates used were U-bottom.

Response: 96 well plates used were flat bottom

line 197: Mention the range of tested concentrations of 3 plant extracts.

Response: The range of tested concentration is 0.75 to 100 mg/mL

Line 203: 48 hours.

Response: corrected as 48 hours.

Line 204: 'resazurin dissolved in water'

Response: Sentence was corrected

Line 204: 'after this incubation' is repeated in the same sentence

Response: after this incubation' is removed

Line 215: Mention which cultures.

Response: M.smegmatis is added

Line 217: Correct as 'plates were further incubated'.

Response: The sentence was corrected.

Section 2.10 says that the MIC plates were incubated for 48 hrs while in section 2.11 incubation time is mentioned as 24 hrs. Why is it different for section 2.11? Pls explain.

Response: MIC was done at 48 hrs incubation. While, we observed synergy at 24 hrs, since a combination showed better action and it was done at 24 hrs.

Line 228: Correct as 'withdrawn at 0, 1, 2, 3, 4, 5, 6 and 7 days, diluted serially and\...'

Response: The sentence was corrected.

Line 229: Mention time of incubation for the plates.

Response : Time of incubation is 48 hours

Line 235: Have you used 'they' for 'pellet'. Pls correct.

Response: The word pellet is added .

Line 343: The concentrations of plant extracts used are exact MICs. How are these sub-minimal?

Response: In synergistic studies, plant extracts acted in subminimal concentration along with the combination of INH/ RIF by reducing the MIC of first line drugs from 4.00 to 0.01 μg/ mL for INH and 2.00 to 0.01 μg/ m for RIF.

Line 375-381: Where are these results shown in the manuscript? These should be represented as a graph and figure number should be mentioned here.

Response: Figure number is included in the manuscript

Line 401: Pls explain this estimation.

Response : The sentences were corrected.

Line 419: Remove 'an'.

Response: The word "an" is removed.
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PONE-D-19-29098R2

Inhibitory activity of traditional plants against Mycobacterium smegmatis and their action on Filamenting temperature sensitive mutant Z (FtsZ) - a cell division protein

PLOS ONE

Dear Dr Ravindran,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Major comments:

1\. The response to the reviewer's concerns should be inserted appropriately in the main text of the revised version.  It is not enough to present only in the rebuttal letter. For example, add "Mycobacterium smegmatis doubling time is 6-8 hours; So beyond 24 hours, drug or extract is not able to prevent the growth of M.smegmatis." as you mentioned in the rebuttal letter

2\. The main component in the plant extracts tested, was deemed to be D-Pinitol, based on RT with the standard. However, no direct evidence has been shown to prove that the component is D-Pinitol.  This limitation should be mentioned in line \#367.

3\. There is confusion in Table-1. While in the main manuscript, Table-1 is showing MIC values, in the "response to reviewer" document, Table-1 shows CFU data (not sure if this is log scale or linear). This requires clarification and fixing. Both tables should be presented in the main manuscript.

4\. The data presented in Supplementary table-1 is unclear as to what it represents. The heading should appear as the caption at the top of the table. Plus, the RT and % area seems to be misplaced.  Also, I see peak\#15 and 17 as D-pinitol, with different RT and %area.  Same discrepancy between HPLC and GC of each of the plant extracts. These are not consistent with the numbers in the main text (line\#312). How do the RT values in the suppl tables of GCMS, correlate with the respective spectrum shown in Suppl-figs-2 to 4 ?. These entities need a full, detailed explanation in the manuscript.

5\. Section 3.5. mentions that about 50% of cells have "Cell wall damage and presumably cell death".  How does this observation correlate with the "Cell elongation study", where it is argued that after treatment with extracts, the cells elongate and fail to replicate and undergo death ?.

6\. Based on the above point, if M. smeg is killed by cell wall damage and cell elongation during treatment with plant extracts, then how would you justify the increase in CFU of treated bacteria in Fig-3. ?

7\. The justification to use 1.5x Mic and 4hrs post treatment for gene expression studies should be mentioned in the methods or results section. Mere citation is insufficient, as this particular study and the organism/conditions used are unique and presumably not presented elsewhere in the literature.

Minor comments:

Lines 369-371. Should be rephrased or removed, since it is speculative. The current study is performed in M. smeg, which is not the causative agent of tuberculosis in humans.

In the rebuttal letter, Milliard reaction should be corrected to Millard reaction, and the justification should be added in the main manuscript.3e

We would appreciate receiving your revised manuscript by May 18 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232482.r006

Author response to Decision Letter 2

14 Apr 2020

Major comments:

1\. The response to the reviewer's concerns should be inserted appropriately in the main text of the revised version. It is not enough to present only in the rebuttal letter. For example, add "Mycobacterium smegmatis doubling time is 6-8 hours; So beyond 24 hours, drug or extract is not able to prevent the growth of M.smegmatis." as you mentioned in the rebuttal letter.

Response: The above mentioned lines were added in the manuscript.

2\. The main component in the plant extracts tested, was deemed to be D-Pinitol, based on RT with the standard. However, no direct evidence has been shown to prove that the component is D-Pinitol. This limitation should be mentioned in line \#367.

Response:

• D-Pinitol detection is based on RT in HPLC with the standard. This is now mentioned in this manuscript.

• Also, GC-MS Mass fragmentation was done for peak of A.nilotica at 5.162 min retension time and G.glabra at 5.169 min retention time which showed 90% similarity index for D- Pinitol. A.marmelos at 5.160 min retention time showed 92% of similarity index .

• HPLC on st andard showed percentage area occupied by D- Pinitol at Retention Time (RT) 10.198 is 100 %.

• HPLC on the three plant HXM extracts A.nilotica, A.marmelos and G.glabra showed percentage area occupied as 45.12 %, 48.33 % and 55.02 % at RT 10.187, 10.143 and 10.135 respectively which matches very closely with RT of standard D-Pinitol (10.198). (Table 1).

• HPLC -- matching of retention time is considered as one of the strongest evidence.

• So based on all these analysis it is concluded the HXM plant extracts has D-Pinitol (Supplementary Figures 7S,8S,9S,10S).

Table 1: GCMS and HPLCanalysis of D-Pinitol with the retention time and percentage area of the plant extracts (We included this table in main manuscript)

S.NO Name Retension time % Area

GCMS

1 A.nilotica 5.162 31.83

2 A.marmelos 5.160 5.86

3 G.glabra 5.169 10.98

HPLC

4 Standard D-Pinitol 10.198 100.00

5 A.nilotica 10.187 45.12

6 A.marmelos 10.143 48.33

7 G.glabra 10.135 55.02

3\. There is confusion in Table-1. While in the main manuscript, Table-1 is showing MIC values, in the "response to reviewer" document, Table-1 shows CFU data (not sure if this is log scale or linear). This requires clarification and fixing. Both tables should be presented in the main manuscript.

Response: In the manuscript we have now included the CFU data (linear) as Table-3.

4\. The data presented in Supplementary table-1 is unclear as to what it represents. The heading should appear as the caption at the top of the table. Plus, the RT and % area seems to be misplaced. Also, I see peak\#15 and 17 as D-pinitol, with different RT and % area. Same discrepancy between HPLC and GC of each of the plant extracts. These are not consistent with the numbers in the main text (line\#312). How do the RT values in the suppl tables of GCMS, correlate with the respective spectrum shown in Suppl-figs-2 to 4 ?. These entities need a full, explanations that should be mentioned in the manuscript.

Response:

• The headings are changed to the top of the table. I have checked and RT and % area are not misplaced.

• Peaks 15 shows RT at 4.958 with 10.94 % area and it indicates the presence of D-Pinitol derivatives and its esters with different molecular weights (GCMS library database). Peak 17 of A.nilotica shows D-Pinitol at RT 5.162 with 31.83 % area. RT of A.nilotica matches with the RT of A.marmelos and G.glabra.

• The numbers in the main text (line\#312) correspond to the RT of D-Pinitol in HPLC reports and they are consistent with the corresponding reports in supplementary figures 7S,8S and 9S.

• To better show the correlation between the spectrum and the respective table, we have now included the original GCMS report as a figure that has both the spectrum as well as the table (Supplementary figures 1S,2S and 3S).

• Explanations on GCMS and HPLC peaks were included in the main manuscript with a table.

5\. Section 3.5. mentions that about 50% of cells have "Cell wall damage and presumably cell death". How does this observation correlate with the "Cell elongation study", where it is argued that after treatment with extracts, the cells elongate and fail to replicate and undergo death ?.

Response:

• The cell elongation histogram (Figure 5h) shows the percentage of elongated cells, from this it can be observed that more than 50 % of cells were elongated. Comparing these percentages with the cell wall damage percentages, it can be derived that there is a percentage of cells that are both elongated and have cell wall damage. Antibacterial compounds can have different modes of action. Cell wall damage is another mechanism of cell death and there need not be a correlation between cell elongation and cell wall damage.

6\. Based on the above point, if M. smeg is killed by cell wall damage and cell elongation during treatment with plant extracts, then how would you justify the increase in CFU of treated bacteria in Fig-3. ?

Response:

• Minimum inhibitory concentration (MIC) is defined as the lowest drug concentration that shows 90% growth inhibition of M. smegmatis (Ref1 and Ref2). The assay adopted in our research also measures this MIC 90

• In our studies, time kill assay, cell elongation and cellular damage studies were carried out at 1x MIC. At 1x MIC, (as per the definition of MIC) 10 % of the organisms which survive at this specific concentration will acclimatize to this conditions and replicates at further time intervals. Thus, an increase in the CFU of the organism is observed in the graph as a function of time (Figure 3a,b). The same observation has been made in other literature reports as mentioned below:

• γ Borono Phosphonate Compounds inhibited 90% of M smegmatis (Ref 3).

• Using Rifampicin at 1 × MIC90 , 10% of plated bacteria which survived, started to grow. With a fractional increase in drug concentration (1.2 × MIC90), the number of survivor colonies dramatically fell and growth of colonies were undetectable at 1.4 × MIC90 (Ref 4).

• Higher concentration of extracts were not used in our study since the objective of this study is to find the efficacy of the plant extracts and drugs combinations at lower concentration to inhibit the action of M.smegmatis.

• We have included the definition of MIC and the cause for increase in CFU in the manuscript.

References:

1\) P.Fyhrquist,I. Laakso,S. Garcia Marco,R.Julkunen-Tiitto,R.Hiltunen, (2014)Antimycobacterial activity of ellagitannin and ellagic acid derivate rich crude extracts and fractions of five selected species of Terminalia used for treatment of infectious diseases in African traditional medicine, South African Journal of Botany, (90), 1-16.

2\) Akiho Yagi, Ryuji Uchida, Hiroshi Hamamoto, Kazuhisa Sekimizu, Ken-ichi Kimura, Hiroshi Tomod (2017), Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis, The Journal of Antibiotics ,( 70), 685--690.

3)Giulia Mancini, Maria Bouda, James M. Gamrat, and John W. Tomsho, (2019), Synthesis and Antimicrobial Evaluation of γ Borono PhosphonateCompounds inEscherichia coliandMycobacterium smegmatis , ACSOmega,(4), 14551−14559.

4\) Jun-Hao Zhu, Bi-Wei Wang, Miaomiao Pan, Yu-Na Zeng, Hesper Rego, and Babak Javid ,Rifampicin can induce antibiotic tolerance in mycobacteria via paradoxical changes in rpoB transcription, Nat Commun. 2018; 9: 4218.

7\. The justification to use 1.5x MIC and 4hrs post treatment for gene expression studies should be mentioned in the methods or results section.

Response: In our studies, cell elongation and cell damage of the M.smegmatis is observed at 4 hours of treatment. Therefore gene expression studies is done at 4 hrs with 1.5 x MIC of plant extracts/ compounds in order to increase the expression of FtsZ. Similar to our studies, selected compounds like Piperidine, Bromo di-methoxy coumarin, Di-methyl amino methyl coumarin at the concentration of 1.5 x MIC increased the FtsZ gene expression studies. The justification is now mentioned in section 3.9.

Reference:

1\. Kartik Mitra, Anju Chada, Mukesh Doble, (2019),Pharmacophore based approach to screen and evaluate novel Mycobacterium cell division inhibitors targeting FtsZ -- A modelling and experimental study, European Journal of Pharmaceutical Sciences, 135(2019)103-112.

Minor comments:

8, Lines 369-371. Should be rephrased or removed, since it is speculative. The current study is performed in M. smeg, which is not the causative agent of tuberculosis in humans.

Response: Sentence was removed.

9, In the rebuttal letter, Milliard reaction should be corrected to Millard reaction, and the justification should be added in the main manuscript.3e

Response: Justification is added in the main manuscript
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Inhibitory activity of traditional plants against Mycobacterium smegmatis and their action on Filamenting temperature sensitive mutant Z (FtsZ) - a cell division protein

PONE-D-19-29098R3

Dear Dr. Ravindran,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0232482.r008
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PONE-D-19-29098R3

Inhibitory activity of traditional plants against *Mycobacterium smegmatis* and their action on Filamenting temperature sensitive mutant Z (FtsZ) - a cell division protein

Dear Dr. Ravindran:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Selvakumar Subbian

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
